drugset / Trial / NCT06688292

The Safety and Effectiveness of Taneasy and Actein in COPD Patients

NCT06688292

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of Taneasy 600mg granules and Actein effervescent tablets 600MG administered twice daily for 14 days in treatment of COPD Disease.

Timeline

Start
2024-09-20
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Actein Small molecule 600 mg
Subject Taneasy Unknown 600 mg